Is Taysha Gene Therapies Inc (TSHA) overvalued? · rev $8.3M
Taysha Gene Therapies Inc (TSHA) is a biotechnology company listed on US.
This page asks whether Taysha Gene Therapies Inc (TSHA) looks expensive on cached numbers — not a short thesis.
Latest reported TSHA revenue for 2024-12-31 was $8.3M. Net income was -$89.3M. Revenue was down 46.1% from 2023-12-31 to 2024-12-31. TSHA currently screens at market cap $640.7M.
TSHA currently screens at market cap $640.7M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next TSHA 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the TSHA stock page for the full model, not this heading.
Not investment advice.